Engineered T cells designed to target and eliminate mesothelioma tumors
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11056781
This study is testing a new treatment for mesothelioma that uses specially designed T cells to better target and fight the cancer while protecting healthy cells, with the hope of improving outcomes for patients facing this tough disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11056781 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new type of engineered T cell therapy aimed at treating mesothelioma, a rare and aggressive cancer. The approach involves creating a dual antigen sensing system that allows T cells to precisely recognize and attack tumor cells while minimizing damage to normal tissues. By utilizing a novel antigen that is primarily found in mesothelioma, the therapy aims to enhance the effectiveness of T cell activation and reduce side effects. The research is designed to lead to clinical trials, potentially offering new hope for patients with this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals diagnosed with mesothelioma who have limited treatment options.
Not a fit: Patients with other types of cancer or those without mesothelioma may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could provide a targeted and effective treatment option for patients suffering from mesothelioma.
How similar studies have performed: Previous research has shown promise in using engineered T cell therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ROYBAL, KOLE T — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: ROYBAL, KOLE T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.